Iovance raises FY 2026 total revenue guidance to $410 million-$420 million
IOVA•Iovance Biotherapeutics raised its full-year 2026 total revenue guidance to $410 million-$420 million from $350 million-$370 million, citing U.S. demand for Amtagvi and Proleukin. Second-quarter total product revenue reached a record $99.3 million.
1. Higher revenue outlook
Iovance raised its full-year 2026 total revenue guidance to $410 million-$420 million from $350 million-$370 million. The midpoint rose by $55 million, or about 15%, implying nearly 60% annual revenue growth. The company cited strong U.S. demand for Amtagvi and Proleukin.
2. Product revenue and centers
Second-quarter 2026 total product revenue reached a record $99.3 million. Iovance's authorized treatment center network expanded to about 100 centers, with a target of at least 110 by year-end 2026.
